To investigate the efficacy and safety of mometasone furoate cream and moisturizing cream in the treatment of infantile allergic dermatitis. Methods A total of 130 children with allergic dermatitis admitted to Huanghua Municipal People's Hospital from June 2021 to May 2022 were randomly divided into observation group and control group, with 65 children in each group. The control group was treated with 0.1% mometasone furoate cream, and the observation group was treated with mometasone furoate cream combined with moisturizing cream. The clinical efficacy, clinical symptoms and skin lesions, quality of life and adverse reactions were compared between the two groups. Results The total effective rate of treatment in the observation group was 96.92%, which was higher than 78.46% in the control group, and the difference was statistically significant (P <0.05). The clinical symptom score and skin lesion score of the two groups were lower than those before treatment, and the observation group were lower than those in the control group (P <0.05). After treatment, the IDQOL score of the two groups was lower than those before treatment, and that in the observation group was lower than that in the control group (P <0.05). The incidence of adverse reaction in the observation group was 7.69%, which was lower than 18.46% of the control group, but the difference was not statistically significant (P >0.05). Conclusion The therapeutic effect of 1% mometasone furoate cream combined with moisturizing cream on infantile dermatitis is better than that of 1% mometasone furoate cream alone. It can effectively improve the clinical symptoms and skin lesions of patients, improve their quality of life, and is not easy to relapse, which is safe and worthy of clinical application.